Eli Lilly (LLY) stock falls as rival Novo Nordisk (NVO) plans to cut Wegovy, Ozempic & Rybelsus U.S. list prices from Jan 1, ...
11hon MSN
Eli Lilly launches new form of obesity drug Zepbound with a month’s worth of doses in one pen
Eli Lilly hopes the device can be more convenient for Zepbound users and lead to more people taking the drug.
The drugmaker is introducing a new, more convenient way to inject its blockbuster obesity drug, Zepbound.
Eli Lilly trades near historical P/E means of ~30x with a 3Y PEG of 1.13x, offering attractive long-term upside potential. Click here to read why LLY is a Buy.
Consolidation of four doses may lower secondary packaging complexity and improve fill-finish throughput predictability, although Lilly has not quantified manufacturing efficiency gains. Multi-dose use ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results